Adaptimmune Therapeutics: Q3 Earnings Insights

Comments
Loading...

 

Adaptimmune Therapeutics ADAP reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM.

Here's what investors need to know about the announcement.

Earnings

Adaptimmune Therapeutics their estimated earnings by 15.38%, reporting an EPS of $-0.3 versus an estimate of $-0.26, which surprised analysts.

Revenue was up $10,000 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0, which was followed by a 3.48% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:

 

Quarter Q2 2021 Q1 2021 Q4 2020 Q3 2020
EPS Estimate -0.24 -0.25 -0.23 -0.25
EPS Actual -0.24 -0.24 -0.24 -0.24
Revenue Estimate 1.36M 1.83M 1.98M 870.00K
Revenue Actual 3.10M 434.00K 1.50M 1.19M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

ADAP Logo
ADAPAdaptimmune Therapeutics PLC
$0.4450-1.13%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum4.51
Growth95.84
Quality-
Value76.43
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: